CN102753159B - 包含异丙酚的药物组合物 - Google Patents

包含异丙酚的药物组合物 Download PDF

Info

Publication number
CN102753159B
CN102753159B CN201080052400.7A CN201080052400A CN102753159B CN 102753159 B CN102753159 B CN 102753159B CN 201080052400 A CN201080052400 A CN 201080052400A CN 102753159 B CN102753159 B CN 102753159B
Authority
CN
China
Prior art keywords
compositions
propofol
oral
pharmaceutical
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080052400.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102753159A (zh
Inventor
巴斯蒂安·泰辛格
索尼娅·泰辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novaliq GmbH
Original Assignee
Novaliq GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq GmbH filed Critical Novaliq GmbH
Publication of CN102753159A publication Critical patent/CN102753159A/zh
Application granted granted Critical
Publication of CN102753159B publication Critical patent/CN102753159B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C19/00—Acyclic saturated compounds containing halogen atoms
    • C07C19/08—Acyclic saturated compounds containing halogen atoms containing fluorine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201080052400.7A 2009-11-23 2010-11-22 包含异丙酚的药物组合物 Active CN102753159B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09014548.3 2009-11-23
EP09014548A EP2332525A1 (en) 2009-11-23 2009-11-23 Pharmaceutical composition comprising propofol
PCT/EP2010/067938 WO2011061332A1 (en) 2009-11-23 2010-11-22 Pharmaceutical composition comprising propofol

Publications (2)

Publication Number Publication Date
CN102753159A CN102753159A (zh) 2012-10-24
CN102753159B true CN102753159B (zh) 2014-03-12

Family

ID=41694756

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080052400.7A Active CN102753159B (zh) 2009-11-23 2010-11-22 包含异丙酚的药物组合物

Country Status (12)

Country Link
US (1) US8796340B2 (enExample)
EP (2) EP2332525A1 (enExample)
JP (1) JP5707009B2 (enExample)
KR (1) KR20120104262A (enExample)
CN (1) CN102753159B (enExample)
AU (1) AU2010320823B2 (enExample)
BR (1) BR112012012108A2 (enExample)
CA (1) CA2776855C (enExample)
ES (1) ES2450423T3 (enExample)
IN (1) IN2012DN03130A (enExample)
MX (1) MX2012005881A (enExample)
WO (1) WO2011061332A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CN103561724B (zh) 2011-05-25 2016-06-29 诺瓦利克有限责任公司 给药给甲的药物组合物
JP6039145B2 (ja) 2011-05-25 2016-12-07 ノバリック ゲーエムベーハー 半フッ化アルカンを基礎にした局所薬学的組成物
GB201116271D0 (en) 2011-09-21 2011-11-02 Univ Cardiff Dispersion anaesthetic device
PT2806886T (pt) 2012-01-23 2017-03-24 Novaliq Gmbh Composições de proteínas estabilizadas baseadas em alcanos semifluorados
EP2895144B1 (en) 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions
MX363182B (es) 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
PL2708228T3 (pl) * 2012-09-12 2018-11-30 Novaliq Gmbh Kompozycje do przemywania oczu
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
EP2944324A1 (de) * 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
EP3206683A4 (en) 2014-10-16 2018-06-13 The Board of Trustees of the Leland Stanford Junior University Novel methods, compounds, and compositions for anesthesia
EP3722274B1 (en) 2015-09-30 2023-06-07 Novaliq GmbH 2-perfluorobutyl pentane for ophthalmic administration
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
DK3442480T3 (da) 2016-06-23 2020-01-13 Novaliq Gmbh Fremgangsmåde til topisk indgivelse
KR102614858B1 (ko) 2016-09-22 2023-12-18 노바리크 게엠베하 안검염 치료에 사용되는 약제학적 조성물
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
MX381639B (es) 2016-12-23 2025-03-13 Novaliq Gmbh Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
JP7814839B2 (ja) 2017-09-27 2026-02-17 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
AU2019246035B2 (en) 2018-03-28 2024-07-18 Novaliq Gmbh Pharmaceutical composition comprising timolol
JP7855312B2 (ja) 2018-04-27 2026-05-08 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
WO2020064549A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
CN114449999A (zh) 2019-09-06 2022-05-06 诺瓦利克有限责任公司 用于治疗葡萄膜炎的眼用组合物
EP3912622A1 (en) 2020-05-19 2021-11-24 tesa Labtec GmbH Oral film for safe administration of api

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496537A (en) * 1995-03-23 1996-03-05 Henry; Richard A. Propofol hydrofluorocarbon propellant formulations
WO2000054588A1 (en) * 1999-03-15 2000-09-21 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6262126B1 (en) * 1995-09-29 2001-07-17 Hasso Meinert Semi-fluorinated alkanes and their use
CN101559229A (zh) * 2008-04-18 2009-10-21 诺瓦利克有限责任公司 在肺内区域作为活性物质载体的半氟化烷的吸入式和滴注式用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124071D0 (en) * 2001-10-08 2001-11-28 Kbig Ltd Improvement in the administration of high boiling point aneasthetics
WO2005067517A2 (en) * 2004-01-02 2005-07-28 Wisconsin Alumni Research Foundation Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers
DE102004030044A1 (de) 2004-06-22 2006-01-12 Birken Gmbh Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels
US9000048B2 (en) * 2006-11-28 2015-04-07 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496537A (en) * 1995-03-23 1996-03-05 Henry; Richard A. Propofol hydrofluorocarbon propellant formulations
US6262126B1 (en) * 1995-09-29 2001-07-17 Hasso Meinert Semi-fluorinated alkanes and their use
WO2000054588A1 (en) * 1999-03-15 2000-09-21 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
CN101559229A (zh) * 2008-04-18 2009-10-21 诺瓦利克有限责任公司 在肺内区域作为活性物质载体的半氟化烷的吸入式和滴注式用途

Also Published As

Publication number Publication date
AU2010320823B2 (en) 2014-06-26
EP2332525A1 (en) 2011-06-15
EP2503999B1 (en) 2013-12-25
US20120238639A1 (en) 2012-09-20
CA2776855C (en) 2017-10-24
WO2011061332A1 (en) 2011-05-26
AU2010320823A1 (en) 2012-07-12
BR112012012108A2 (pt) 2016-04-05
EP2503999A1 (en) 2012-10-03
KR20120104262A (ko) 2012-09-20
ES2450423T3 (es) 2014-03-24
JP5707009B2 (ja) 2015-04-22
CA2776855A1 (en) 2011-05-26
MX2012005881A (es) 2012-06-19
IN2012DN03130A (enExample) 2015-09-18
CN102753159A (zh) 2012-10-24
JP2013511496A (ja) 2013-04-04
US8796340B2 (en) 2014-08-05

Similar Documents

Publication Publication Date Title
JP5707009B2 (ja) プロポフォールを含有する医薬組成物
JP7621220B2 (ja) 疾患の処置のための鼻腔内エピネフリン製剤及び方法
ES2875742T3 (es) Métodos para aumentar la inhibición tónica y tratamiento del síndrome de Angelman
ES2873964T3 (es) Nuevas composiciones analgésicas
CN110505873B (zh) 鼻内肾上腺素制剂及治疗疾病的方法
JP2020040958A (ja) 炎症を低減させるための新規揮発性麻酔薬製剤およびその使用法
US5496537A (en) Propofol hydrofluorocarbon propellant formulations
BR112020023741A2 (pt) filme, métodos de tratamento de condições em pacientes humanos e de fabricação de filmes e uso de filme
BRPI0406674B1 (pt) composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável, uso de uma composição, dispositivo para pulverização, e, processo para preparar uma composição
CA2881158A1 (en) Pharmaceutical composition comprising diamorphine for intranasal administration
EP4225271A1 (en) Compositions and methods for lowering intracranial pressure by intranasal agent administration
EP3407875A1 (en) Aqueous pharmaceutical formulation comprising propofol
HK1172272A (en) Pharmaceutical composition comprising propofol
WO2021001601A1 (en) Methods for administering (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide
HK40092206A (en) Intranasal epinephrine formulations and methods for the treatment of disease
HK40054634B (en) Aqueous paediatric retinol formulations
EA052369B1 (ru) Интраназальные составы на основе эпинефрина и способы лечения заболевания

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1172272

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant